Research programme: selective kinase inhibitors - BioMed X/ Merck

Drug Profile

Research programme: selective kinase inhibitors - BioMed X/ Merck

Latest Information Update: 07 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioMed X; Merck & Co; University of Heidelberg
  • Class Small molecules
  • Mechanism of Action DNA repair enzyme modulators; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Inflammation

Most Recent Events

  • 03 Mar 2016 BioMed X and Merck extend agreement to co-develop DNA damage and repair mechanisms therapeutics in Germany for Cancer
  • 13 Jan 2016 Merck acquires all generated research and development results in the field of selective kinase inhibitors from BioMed X
  • 13 Jan 2016 Early research in Cancer in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top